Sign in or create an account to add this stock to your watchlist.
About Cormedix (NYSEAMERICAN:CRMD)
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CRMD
CUSIPN/A
Phone+1-908-5179500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-16,300.49%
Return on Equity-318.95%
Return on Assets-227.65%
Miscellaneous
EmployeesN/A
Outstanding Shares81,900,000
Cormedix (NYSEAMERICAN:CRMD) Frequently Asked Questions
What is Cormedix's stock symbol?
Cormedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."
How were Cormedix's earnings last quarter?
Cormedix (NYSEAMERICAN:CRMD) announced its quarterly earnings data on Monday, March, 19th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The biotechnology company earned $0.09 million during the quarter. Cormedix had a negative return on equity of 318.95% and a negative net margin of 16,300.49%. View Cormedix's Earnings History.
When is Cormedix's next earnings date?
What price target have analysts set for CRMD?
2 brokerages have issued 1 year price targets for Cormedix's stock. Their predictions range from $3.00 to $4.00. On average, they expect Cormedix's stock price to reach $3.50 in the next year. View Analyst Ratings for Cormedix.
Are investors shorting Cormedix?
Cormedix saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 6,762,370 shares, an increase of 2.2% from the April 13th total of 6,619,276 shares. Based on an average daily volume of 623,608 shares, the days-to-cover ratio is presently 10.8 days. Currently, 8.8% of the shares of the stock are short sold.
Who are some of Cormedix's key competitors?
Some companies that are related to Cormedix include OncoCyte (OCX), InMed Pharmaceuticals (IMLFF), Navidea Biopharmaceuticals (NAVB), Botanix Pharmaceuticals (BOT), IntelGenx Technologies (IGX), BELLUS Health (BLU), Medicenna Therapeutics (MDNA), NovaBay Pharmaceuticals (NBY), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), OptiBiotix Health (OPTI), Scancell (SCLP), Synthetic Biologics (SYN), DiaMedica Therapeutics (DMA) and Antibe Therapeutics (ATE).
Who are Cormedix's key executives?
Cormedix's management team includes the folowing people:
- Mr. Khoso Baluch, CEO & Director (Age 60)
- Mr. Robert W. Cook, Chief Financial Officer (Age 62)
- Mr. John L. Armstrong Jr., MBA, Head of HR & Exec. VP of Technical Operations (Age 74)
- Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations
- Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance
Has Cormedix been receiving favorable news coverage?
Media coverage about CRMD stock has trended positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cormedix earned a news impact score of 0.37 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.47 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Cormedix?
Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cormedix's stock price today?
One share of CRMD stock can currently be purchased for approximately $0.17.
How big of a company is Cormedix?
Cormedix has a market capitalization of $18.50 million.
How can I contact Cormedix?
Cormedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.
MarketBeat Community Rating for Cormedix (CRMD)
MarketBeat's community ratings are surveys of what our community members think about Cormedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cormedix (NYSEAMERICAN:CRMD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Cormedix in the last 12 months. Their average twelve-month price target is $2.50, suggesting that the stock has a possible upside of 1,335.96%. The high price target for CRMD is $3.00 and the low price target for CRMD is $2.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $2.50 | $3.50 | $3.6667 | $3.6667 |
| Price Target Upside: | 1,335.96% upside | 1,844.44% upside | 474.53% upside | 474.53% upside |
Cormedix (NYSEAMERICAN:CRMD) Consensus Price Target History
Cormedix (NYSEAMERICAN:CRMD) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 5/23/2018 | HC Wainwright | Lower Price Target | Buy ➝ Buy | $4.00 ➝ $2.00 |  |
| 8/10/2017 | Rodman & Renshaw | Lower Price Target | Buy ➝ Buy | $5.00 ➝ $3.00 | |
| 4/24/2017 | FBR & Co | Reiterated Rating | Buy | | |
(Data available from 5/23/2016 forward)
Cormedix (NYSEAMERICAN:CRMD) Earnings History and Estimates Chart
Cormedix (NYSEAMERICAN CRMD) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/23/2018 | | | | | | | | |
| 3/19/2018 | Q4 2017 | | ($0.15) | | $0.09 million | View | N/A | |
| 11/9/2017 | Q3 2017 | | ($0.14) | | $0.06 million | View | N/A | |
| 8/9/2017 | Q2 2017 | ($0.16) | ($0.14) | $0.15 million | $0.14 million | View | N/A | |
| 5/10/2017 | Q1 2017 | ($0.15) | ($0.19) | $0.09 million | $0.04 million | View | N/A | |
| 3/16/2017 | Q4 2016 | ($0.22) | ($0.16) | $0.06 million | $0.12 million | View | N/A | |
| 11/9/2016 | Q3 2016 | ($0.15) | ($0.23) | $0.05 million | $0.04 million | View | N/A | |
| 8/5/2016 | Q216 | ($0.11) | ($0.13) | $119.97 million | $16.51 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.09) | ($0.12) | $0.11 million | $0.04 million | View | N/A | |
| 3/16/2016 | Q4 2015 | ($0.16) | ($0.11) | $0.07 million | $0.02 million | View | N/A | |
| 11/12/2015 | Q3 | ($0.13) | ($0.14) | $0.12 million | $0.04 million | View | Listen | |
| 8/6/2015 | Q2 2015 | ($0.13) | ($0.13) | $0.08 million | $0.12 million | View | N/A | |
| 5/7/2015 | Q1 2015 | ($0.10) | ($0.23) | $0.07 million | $0.03 million | View | N/A | |
| 3/12/2015 | Q4 2014 | ($0.12) | ($0.09) | $0.08 million | $0.09 million | View | N/A | |
| 11/13/2014 | Q3 2014 | ($0.09) | ($0.09) | $0.08 million | $0.05 million | View | N/A | |
| 8/14/2014 | Q2 2014 | ($0.13) | ($0.26) | $0.02 million | $0.04 million | View | N/A | |
| 5/15/2014 | Q1 2014 | | ($0.16) | | $0.01 million | View | N/A | |
| 3/31/2014 | Q4 2013 | | ($0.22) | | | View | N/A | |
| 11/19/2013 | Q3 2013 | | ($0.18) | | | View | N/A | |
| 8/14/2013 | Q2 2013 | | ($0.15) | | | View | N/A | |
| 5/14/2013 | Q1 2013 | | ($0.10) | | | View | N/A | |
| 3/27/2013 | Q4 2012 | | ($0.10) | | | View | N/A | |
| 11/13/2012 | Q3 2012 | | ($0.06) | | | View | N/A | |
| 8/13/2012 | Q2 2012 | | ($0.05) | | | View | N/A | |
| 5/15/2012 | Q1 2012 | | ($0.08) | | | View | N/A | |
| 3/19/2012 | Q4 2011 | | $0.03 | | | View | N/A | |
| 11/10/2011 | Q3 2011 | | ($0.23) | | | View | N/A | |
| 8/9/2011 | Q2 2011 | ($0.20) | ($0.22) | | | View | N/A | |
| 5/10/2011 | Q1 2011 | ($0.13) | ($0.17) | | | View | N/A | |
| 3/11/2011 | Q4 2010 | ($0.09) | ($0.05) | | | View | N/A | |
| 11/9/2010 | Q3 2010 | ($0.18) | ($0.12) | | | View | N/A | |
| 8/12/2010 | Q2 2010 | ($0.18) | ($0.10) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Cormedix (NYSEAMERICAN:CRMD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cormedix (NYSEAMERICAN CRMD) Insider Trading and Institutional Ownership History
Cormedix (NYSEAMERICAN CRMD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/12/2017 | Jr. John L Armstrong | VP | Buy | 20,833 | $0.48 | $9,999.84 | 20,833 | |
| 12/12/2017 | Khoso Baluch | CEO | Buy | 104,166 | $0.48 | $49,999.68 | 225,373 | |
| 12/12/2017 | Robert W Cook | CFO | Buy | 52,083 | $0.48 | $24,999.84 | 102,083 | |
| 12/12/2017 | Steven W Lefkowitz | Director | Buy | 135,416 | $0.48 | $64,999.68 | | |
| 8/18/2017 | Khoso Baluch | CEO | Buy | 36,207 | $0.42 | $15,206.94 | 121,207 | |
| 8/18/2017 | Mehmood Khan | Director | Buy | 400,000 | $0.39 | $156,000.00 | 50,000 | |
| 8/17/2017 | Myron Kaplan | Director | Buy | 80,000 | $0.40 | $32,000.00 | 180,000 | |
| 8/14/2017 | Myron Kaplan | Director | Buy | 50,000 | $0.35 | $17,500.00 | 100,000 | |
| 5/30/2017 | Cora M Tellez | Director | Buy | 7,550 | $0.42 | $3,171.00 | 182,371 | |
| 5/17/2017 | Khoso Baluch | CEO | Buy | 75,000 | $0.48 | $36,000.00 | 85,000 | |
| 5/16/2017 | Cora M Tellez | Director | Buy | 50,000 | $0.48 | $24,000.00 | 174,821 | |
| 5/15/2017 | Janet Dillione | Director | Buy | 21,231 | $0.48 | $10,190.88 | 39,969 | |
| 5/15/2017 | Robert W Cook | CFO | Buy | 50,000 | $0.50 | $25,000.00 | 50,000 | |
| 5/1/2017 | Cora M Tellez | Director | Buy | 4,800 | $0.66 | $3,168.00 | 124,821 | |
| 3/30/2017 | Cora M Tellez | Director | Buy | 1,950 | $1.66 | $3,237.00 | 120,021 | |
| 2/28/2017 | Cora M Tellez | Director | Buy | 1,540 | $2.10 | $3,234.00 | 118,071 | |
| 2/7/2017 | Antony Pfaffle | Insider | Sell | 10,000 | $2.00 | $20,000.00 | 10,000 | |
| 1/30/2017 | Cora M Tellez | Director | Buy | 1,780 | $1.79 | $3,186.20 | 116,531 | |
| 12/30/2016 | Cora M Tellez | Director | Buy | 1,990 | $1.58 | $3,144.20 | 114,751 | |
| 12/9/2016 | Khoso Baluch | CEO | Buy | 10,000 | $1.77 | $17,700.00 | 10,000 | |
| 11/30/2016 | Cora M Tellez | Director | Buy | 1,800 | $1.80 | $3,240.00 | 112,761 | |
| 10/31/2016 | Cora M Tellez | Director | Buy | 1,475 | $2.15 | $3,171.25 | 110,961 | |
| 10/21/2016 | Antony Pfaffle | Insider | Sell | 20,000 | $2.23 | $44,600.00 | 20,000 | |
| 9/22/2016 | Janet Dillione | Director | Buy | 15,000 | $2.66 | $39,900.00 | 15,000 | |
| 8/25/2016 | Taunia Markvicka | Director | Buy | 18,600 | $1.65 | $30,690.00 | 22,600 | |
| 8/19/2016 | Cora M Tellez | Director | Buy | 12,500 | $1.73 | $21,625.00 | 109,486 | |
| 6/21/2016 | Antony Pfaffle | Insider | Sell | 29,657 | $2.14 | $63,465.98 | 10,000 | |
| 6/20/2016 | Antony Pfaffle | Insider | Sell | 10,000 | $2.16 | $21,600.00 | 10,000 | |
| 6/15/2016 | Antony Pfaffle | Insider | Sell | 4,900 | $2.21 | $10,829.00 | 4,900 | |
| 6/13/2016 | Antony Pfaffle | Insider | Sell | 5,443 | $2.27 | $12,355.61 | 5,000 | |
| 6/9/2016 | Antony Pfaffle | Insider | Sell | 10,000 | $2.38 | $23,800.00 | 10,000 | |
| 6/8/2016 | Janet Dillione | Director | Buy | 3,738 | $2.67 | $9,980.46 | 18,738 | |
| 6/3/2016 | Matthew Duffy | Director | Sell | 46,106 | $2.73 | $125,869.38 | 28,571 | |
| 5/31/2016 | Steven W Lefkowitz | Director | Sell | 50,000 | $2.88 | $144,000.00 | 159,599 | |
| 5/25/2016 | Cora M Tellez | Director | Buy | 8,600 | $2.90 | $24,940.00 | 96,986 | |
| 5/24/2016 | Antony Pfaffle | Insider | Sell | 12,700 | $2.73 | $34,671.00 | 12,700 | |
| 5/24/2016 | Antony Pfaffle | Insider | Sell | 12,700 | $2.73 | $34,671.00 | 12,700 | |
| 5/23/2016 | Antony Pfaffle | Insider | Sell | 15,000 | $2.89 | $43,350.00 | 10,000 | |
| 5/23/2016 | Steven W Lefkowitz | Director | Sell | 30,000 | $2.93 | $87,900.00 | 132,525 | |
| 5/19/2016 | Antony Pfaffle | Insider | Sell | 12,300 | $2.82 | $34,686.00 | 12,300 | |
| 5/16/2016 | Antony Pfaffle | Insider | Sell | 60,000 | $2.68 | $160,800.00 | 60,000 | |
| 6/30/2015 | Randy Milby | CEO | Buy | 1,610 | $3.88 | $6,246.80 | | |
| 6/23/2015 | Taunia Markvicka | Director | Buy | 4,000 | $4.81 | $19,240.00 | | |
| 6/15/2015 | Randy Milby | CEO | Buy | 1,245 | $5.02 | $6,249.90 | | |
| 6/4/2015 | Matthew Duffy | Director | Sell | 30,000 | $6.48 | $194,400.00 | | |
| 5/29/2015 | Randy Milby | CEO | Buy | 1,026 | $6.09 | $6,248.34 | | |
| 2/27/2015 | Randy Milby | CEO | Buy | 1,211 | $5.16 | $6,248.76 | | |
| 2/13/2015 | Randy Milby | CEO | Buy | 1,911 | $3.27 | $6,248.97 | | |
| 1/30/2015 | Randy Milby | CEO | Buy | 2,016 | $3.10 | $6,249.60 | | |
| 12/15/2014 | Randy Milby | CEO | Buy | 4,734 | $1.32 | $6,248.88 | | |
| 11/28/2014 | Randy Milby | CEO | Buy | 4,464 | $1.40 | $6,249.60 | | |
| 11/14/2014 | Cora M Tellez | Director | Buy | 11,086 | $1.52 | $16,850.72 | | |
| 11/14/2014 | Randy Milby | CEO | Buy | 4,111 | $1.52 | $6,248.72 | | |
| 10/31/2014 | Randy Milby | CEO | Buy | 3,434 | $1.82 | $6,249.88 | | |
| 9/30/2014 | Randy Milby | CEO | Buy | 3,324 | $1.88 | $6,249.12 | | |
| 9/15/2014 | Randy Milby | CEO | Buy | 3,654 | $1.71 | $6,248.34 | | |
| 8/29/2014 | Randy Milby | CEO | Buy | 3,125 | $2.00 | $6,250.00 | | |
| 8/15/2014 | Randy Milby | CEO | Buy | 3,140 | $1.99 | $6,248.60 | | |
| 7/31/2014 | Randy Milby | CEO | Buy | 6,250 | $2.00 | $12,500.00 | | |
| 6/30/2014 | Randy Milby | CEO | Buy | 2,732 | $1.83 | $4,999.56 | | |
| 12/13/2013 | Steven W Lefkowitz | Insider | Buy | 18,000 | $0.78 | $14,040.00 | | |
(Data available from 1/1/2013 forward)
Cormedix (NYSEAMERICAN CRMD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | CorMedix's (CRMD) CEO Khoso Baluch on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 8:13 AM |
 | Cormedix Inc. Reports First Quarter Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 5:52 PM |
 | Cormedix (CRMD) Short Interest Update
www.americanbankingnews.com - May 9 at 5:49 PM |
| CorMedix Inc. to Report First Quarter 2018 Financial Results on Tuesday, May 15
finance.yahoo.com - May 9 at 8:13 AM |
| CorMedix Revises Timeline and Announces Changes to Lock-It-100 Study Management
finance.yahoo.com - April 27 at 8:25 AM |
| Cormedix (CRMD) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - April 26 at 2:34 AM |
| Short Interest in Cormedix (CRMD) Grows By 12.6%
www.americanbankingnews.com - April 24 at 6:38 PM |
| CorMedix Inc. (CRMD) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - April 11 at 2:27 AM |
| HC Wainwright Analysts Give CorMedix (CRMD) a $3.00 Price Target
www.americanbankingnews.com - April 10 at 11:38 PM |
| HC Wainwright Analysts Give CorMedix (CRMD) a $4.00 Price Target
www.americanbankingnews.com - April 7 at 12:27 PM |
| Zacks Investment Research Lowers CorMedix (CRMD) to Sell
www.americanbankingnews.com - April 4 at 8:32 PM |
| CorMedix (CRMD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 3 at 8:49 PM |
| CorMedix (CRMD) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 29 at 7:58 PM |
| CorMedix (CRMD) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 27 at 9:44 PM |
| CorMedix Inc. (CRMD) Sees Large Increase in Short Interest
www.americanbankingnews.com - March 26 at 6:52 PM |
| CorMedix (CRMD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 22 at 8:42 PM |
| Zacks Investment Research Upgrades CorMedix (CRMD) to Buy
www.americanbankingnews.com - March 21 at 8:22 PM |
 | Biotech Stocks' Research Reports Released on CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:41 AM |
 | Cormedix, Inc.: CorMedix Inc. Makes NYSE American Section 610(b) Public Announcement
www.finanznachrichten.de - March 20 at 5:21 PM |
| CorMedix Inc. Makes NYSE American Section 610(b) Public Announcement
finance.yahoo.com - March 20 at 5:21 PM |
| Cormedix Inc. Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 19 at 5:22 PM |
| Cormedix, Inc.: CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results on Monday, March 19
www.finanznachrichten.de - March 13 at 7:22 PM |
| CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results on Monday, March 19
finance.yahoo.com - March 13 at 8:18 AM |
| Short Interest in CorMedix Inc. (CRMD) Rises By 5.1%
www.americanbankingnews.com - March 9 at 6:22 PM |
| CorMedix (CRMD) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 8 at 1:10 AM |
| Short Interest in CorMedix Inc. (CRMD) Declines By 0.3%
www.americanbankingnews.com - March 1 at 1:52 AM |
| CorMedix Inc. Provides Update on Its Financing Plans in Connection with Its Ongoing LOCK-IT 100 Clinical Study
finance.yahoo.com - February 27 at 5:58 PM |
| CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma
finance.yahoo.com - February 26 at 8:13 AM |
| Why CorMedix Inc. (CRMD) Shares Took a Nosedive Today
finance.yahoo.com - February 20 at 5:50 PM |
| CorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin(R) for Interim Efficacy Analysis
finance.yahoo.com - February 20 at 8:13 AM |
| CorMedix Inc. (CRMD) Short Interest Update
www.americanbankingnews.com - February 9 at 8:28 PM |
 | Technical Perspectives on Biotech Stocks -- CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics
www.bizjournals.com - February 9 at 9:21 AM |
| CorMedix Inc. (CRMD) Short Interest Up 8.3% in January
www.americanbankingnews.com - January 24 at 6:10 PM |
| CorMedix Inc. (CRMD) Short Interest Down 10.2% in December
www.americanbankingnews.com - January 11 at 2:36 AM |
| ETFs with exposure to CorMedix, Inc. : January 1, 2018
finance.yahoo.com - January 1 at 5:12 PM |
| CorMedix, Inc. :CRMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 28 at 1:16 PM |
| Short Interest in CorMedix Inc. (CRMD) Increases By 20.4%
www.americanbankingnews.com - December 27 at 6:38 PM |
| ETFs with exposure to CorMedix, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 5:16 PM |
| CorMedix Inc. (CRMD) CFO Robert W. Cook Acquires 52,083 Shares
www.americanbankingnews.com - December 14 at 6:50 PM |
| Khoso Baluch Buys 104,166 Shares of CorMedix Inc. (CRMD) Stock
www.americanbankingnews.com - December 14 at 6:28 PM |
| CorMedix Inc. (CRMD) Director Steven W. Lefkowitz Acquires 135,416 Shares
www.americanbankingnews.com - December 14 at 6:26 PM |
| ETFs with exposure to CorMedix, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:43 PM |
| CorMedix Inc. Announces Acceptance of Final Post-Marketing Study Data to be Published in the European Journal of Clinical Microbiology and Infectious Diseases
finance.yahoo.com - December 5 at 10:14 AM |
| CorMedix Inc (CRMD): Should The Recent EPS Drop Worry You?
finance.yahoo.com - December 4 at 5:16 PM |
| CorMedix Inc. to Host Seminar on Hemodialysis Catheter Complications at 17th Annual Conference on Nephrology
finance.yahoo.com - November 29 at 9:37 AM |
| Short Interest in CorMedix Inc. (CRMD) Grows By 21.6%
www.americanbankingnews.com - November 27 at 7:48 PM |
| CorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management Team
finance.yahoo.com - November 20 at 6:34 PM |
Cormedix (NYSEAMERICAN:CRMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cormedix (NYSEAMERICAN:CRMD) Income Statement, Balance Sheet and Cash Flow Statement
Cormedix (NYSEAMERICAN CRMD) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
